Motif Bio plc

Mofit BioSciencesMotif Bio plc (LSE: MTFB, NASDAQ: MTFB) is developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria.  

The data from Motif’s Phase III REVIVE-1 clinical trial of its lead antibiotic, iclaprim, support the belief that iclaprim is safe and effective.  In August 2017, Motif announced that the last patient completed the treatment phase in REVIVE-2, the second Phase III clinical trial investigating the safety and efficacy of iclaprim in patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI).  Data from REVIVE-2, which uses an identical protocol to REVIVE-1 but has different trial centers, are expected in the fourth quarter of 2017. The company believes that the successful completion of these two pivotal Phase III trials satisfy both FDA and EMA requirements for regulatory submission for an IV formulation of iclaprim in the treatment of ABSSSI. The company remains on track to submit a New Drug Application in the first quarter of 2018 in the United States and a Marketing Authorisation Application in the first half of 2018 in Europe for iclaprim for the treatment of ABSSSI. 

In September 2017, Iclaprim was granted Orphan Drug Designation by the FDA for the treatment of Staphylococcus aureus lung infections in patients with Cystic Fibrosis. This designation grants special status to a drug or biologic under development to treat a rare disease or condition and qualifies Motif for various development incentives including tax credits for qualified clinical testing, waiver of user fees, and potentially up to seven years of market exclusivity for the given indication.



Graham Lumsden- Chief Executive Officer
Rob Dickey IV- Chief Financial Officer
David Huang M.D., Ph.D., JD- Chief Medical Officer
Rajesh Shukla Ph.D.- Vice President, Clinical Operations

Board of Directors

Richard C.E. Morgan- (Chairman) Chief Executive Officer, Amphion Innovations
Dr. Craig Albanese- Chief Operating Officer, New York Presbyterian/ Morgan Stanley Children's Hospital
Robert Bertoldi- President and Cheif Financial Officer, Amphion Innovations
Zaki Hosny- (Deputy Chairman)
Charlotta Ginman - Financial and operational professional. Held senior roles at  JP Morgan, Deutsche Bank and UBS.
Jon Gold - Senior Financial Analyst, Federated Investments
Graham Lumsden- Executive Director
Dr. Mary Lake Polan - Board of Directors, Wyeth Corporation, formally Professor and Chair emeritus, Department of Obstetrics and Gynecology, Stanford University School of Medicine
Bruce Williams - Biotechnology Industry Consultant, formally held senior marketing positions at Celgene Corp., and Ortho Biotech, a Johnson & Johnson company



Top of page